Sugi Predict

Sugi Predict / Compounds / SCHEMBL10115633

SCHEMBL10115633

SCHEMBL10115633

Cc1cc(NC(=O)N2CCC(NS(=O)(=O)C(C)(C)C)CC2)cc2c1OCO2

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ LMNA P02545 3/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ MAPT P10636 5/20 0.39
▸ CCR8 P51685 1/20 0.38
▸ EPHX2 P34913 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ TSHR P16473 2/20 0.37
▸ POLB P06746 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HTT P42858 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115977 0.86 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPSR1MAPTCCR8
SCHEMBL10114645 0.85 SMN1; SMN2 (0.60) SMN1; SMN2LMNANPSR1MAPTEPHX2
SCHEMBL10115632 0.80 CCR8 (0.41) SMN1; SMN2LMNANPSR1MAPTCCR8
SCHEMBL10115636 0.78 SMN1; SMN2 (0.60) SMN1; SMN2LMNANPSR1MAPTGAA
SCHEMBL12882637 0.78 LMNA (0.40) SMN1; SMN2LMNANPSR1MAPTCCR8
SCHEMBL10115707 0.77 USP2 (0.47) LMNANPSR1NPC1TSHRUSP2
SCHEMBL10115842 0.77 LMNA (0.47) SMN1; SMN2LMNANPSR1MAPTCCR8
SCHEMBL10115527 0.76 LMNA (0.66) LMNANPSR1MAPTGAANPC1
SCHEMBL10115721 0.76 LMNA (0.40) LMNANPSR1MAPTCCR8NPC1
SCHEMBL10115627 0.76 LMNA (0.40) SMN1; SMN2LMNANPSR1MAPTCCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R SMN1; SMN2 2213/4885LMNA 1925/4885NPSR1 7/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2197/4885LMNA 2068/4885NPSR1 8/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885LMNA 1857/4885NPSR1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.